Estrogen and thrombosis: A bench to bedside review.

@article{AbouIsmail2020EstrogenAT,
  title={Estrogen and thrombosis: A bench to bedside review.},
  author={Mouhamed Yazan Abou‐Ismail and Divyaswathi Citla Sridhar and Lalitha Nayak},
  journal={Thrombosis research},
  year={2020},
  volume={192},
  pages={
          40-51
        }
}
Hyperestrogenemia resulting from a granulosa cell tumor and causing pulmonary thromboembolism: a case report.
TLDR
The case of a 59-year-old woman, postmenopausal for 4 years, not using hormone replacement therapy, who was admitted into the emergency room with shortness of breath and increased abdominal volume and was diagnosed with pulmonary thromboembolism and a large left adnexal tumor is reported.
Global coagulation assays in hypercoagulable states
TLDR
A review of the use and limitations of global coagulation assays in healthy controls as well as hypercoagulable conditions is provided.
Risk of thromboembolic complications during hormone therapy
TLDR
The review presents modern data of the hormonal contraceptives and hormone replacement therapy drugs on the risk of thromboembolic complications and the use of hormonal therapy in women with extragenital diseases is discussed.
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
TLDR
Higher thromboembolic risk may be related to the specificity of JAK inhibitor action, such that preferentially blocking one signaling pathway upsets the balance between pro and anti-thrombotic activities.
Thromboembolism and Oral Contraceptives During the COVID-19 Pandemic: A Disproportionality Analysis Within the Spanish Pharmacovigilance Database
TLDR
The reported disproportionality of TEs in women on SHCs rose during the pandemic period, which suggests a potential interaction of the drug (SHC) with COVID-19, which led to an increased risk of TES in women exposed to both factors.
Contraception for Adolescents and Young Women with Type 2 Diabetes–Specific Considerations
TLDR
Progestin-only or nonhormonal long-acting reversible contraception (LARC) should be recommended for women with T2D with compliance issues or adverse cardiovascular risk profiles.
Sex Differences in Hemostatic Factors in Patients With Ischemic Stroke and the Relation With Migraine—A Systematic Review
TLDR
It is suggested that sex differences exist in the activation of the hemostatic system in ischemic stroke, and women seem to lean more toward increased levels of procoagulant factors whereas men exhibit increased level of coagulation inhibitors.
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception
TLDR
To determine if use of hormonal contraception increases risk of venous and arterial thromboembolism in women with COVID-19 and to maintain the currency of the evidence, using a living systematic review approach.
Osteonecrosis of the Jaws in Patients with Hereditary Thrombophilia/Hypofibrinolysis—From Pathophysiology to Therapeutic Implications
TLDR
It is found that hereditary prothrombotic abnormalities are common in patients with ONJ refractory to conventional medical and dental treatments and frequently acquired prothROMBotic abnormalities coexist with hereditary ones and enhance their negative effect on the bone.
Awareness About Venous Thromboembolism Among Saudi Female Who Use Oral Contraceptive Pills: A Descriptive Cross-Sectional Study
TLDR
The Saudi female population had a low level of knowledge and awareness of deep vein thrombosis (DVT) and pulmonary embolism (PE) in OCP users, and efforts are needed to increase awareness of these preventable diseases in the Saudifemale population.
...
1
2
...

References

SHOWING 1-10 OF 124 REFERENCES
Estrogen plus progestin and risk of venous thrombosis
TLDR
Estrogen plus progestin therapy was associated with doubling the risk of venous thrombosis and increased the risks associated with age, overweight or obesity, and factor V Leiden.
Estrogen-associated thromboembolism.
  • S. Wessler
  • Biology, Medicine
    Annals of epidemiology
  • 1992
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
TLDR
Hormonal therapy was not associated with an increased risk of recurrent VTE in women receiving therapeutic anticoagulation and the observed increasedrisk of abnormal uterine bleeding with rivaroxaban needs further exploration.
Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.
TLDR
The indication of a lower or a lack of VTE risk associated with the use of progestin-only contraceptives and with transdermal HRT suggests that these therapies may be safer than combination oral contraceptive pills and oral HRT for women in whom oral estrogen therapy is considered contraindicated.
Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor α.
TLDR
It is demonstrated that a chronic high physiologic level of estradiol (E2) in mice leads to a marked decrease in platelet responsiveness ex vivo and in vivo compared with ovariectomized controls and point to new potential antithrombotic and vasculoprotective therapeutic strategies.
Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy
TLDR
The data suggest that the route of hormone administration, patient demographics, and patient comorbidities all affect estrogen’s link with VTE, and Clinicians should avoid the use of ethinyl estradiol and progestins should be avoided for transgender individuals.
Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis.
TLDR
Observational evidence warranting low confidence suggests that compared to transdermal ET, oral ET may be associated with increased risk of VTE and DVT, but not MI.
...
1
2
3
4
5
...